BioInvent International
Ingrid Teige possesses extensive experience in the biotechnology and pharmaceutical sectors, currently serving as Vice President of Preclinical at BioInvent International AB since April 2013. Prior to this role, Ingrid held the position of Oncology Director at BioInvent from April 2009 to April 2013 and worked as a Principal Research Scientist during that period. Earlier in Ingrid's career, engagements included a role as Research Scientist at LEO Pharma from 2005 to 2009 and participation in Medical Inflammation Research at Lund University from 2000 to 2005.
This person is not in any teams
This person is not in any offices
BioInvent International
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.